Kazama JJ - Search Results

1

Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy.

Koda R, Kazama JJ, Matsuo K, Kawamura K, Yamamoto S, Wakasugi M, Takeda T, Narita I. Koda R, et al. Among authors: kazama jj. Clin Exp Nephrol. 2015 Aug;19(4):710-7. doi: 10.1007/s10157-014-1045-3. Epub 2014 Nov 11. Clin Exp Nephrol. 2015. PMID: 25384431 Free PMC article.

2

Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients.

Nakanishi S, Kazama JJ, Shigematsu T, Iwasaki Y, Cantor TL, Kurosawa T, Fukagawa M. Nakanishi S, et al. Among authors: kazama jj. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S172-4. doi: 10.1053/ajkd.2001.27436. Am J Kidney Dis. 2001. PMID: 11576948 Clinical Trial.

3

Hypersensitivity to paraoxybenzoic Acid esters (parabens) in a dialysis patient.

Sato K, Kazama JJ, Wada Y, Maruyama H, Narita I, Gejyo F, Sugiyama K, Satoh H. Sato K, et al. Among authors: kazama jj. Nephron. 2002;92(3):728-9. doi: 10.1159/000064076. Nephron. 2002. PMID: 12372968

4

Association of the MCP-1 gene polymorphism A-2518G with carpal-tunnel syndrome in hemodialysis patients.

Omori K, Kazama JJ, Song J, Goto S, Takada T, Saito N, Sakatsume M, Narita I, Gejyo F. Omori K, et al. Among authors: kazama jj. Amyloid. 2002 Sep;9(3):175-82. doi: 10.3109/13506120209114819. Amyloid. 2002. PMID: 12408680

5

Successful perioperative blood purification therapy in patients with maintenance hemodialysis therapy who underwent living donor liver transplantation.

Kazama JJ, Takahashi N, Ito Y, Watanabe Y, Iino N, Iguchi S, Oyanagi A, Obayashi H, Ito S, Maruyama H, Narita I, Yamamoto S, Sato Y, Tsuchiya A, Ichida T, Gejyo F. Kazama JJ, et al. Clin Nephrol. 2003 Mar;59(3):229-33. doi: 10.5414/cnp59229. Clin Nephrol. 2003. PMID: 12653270

6

Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia.

Kazama JJ, Omori T, Ei I, Ei K, Oda M, Maruyama H, Narita I, Gejyo F, Shigematsu T, Fukagawa M. Kazama JJ, et al. Clin Exp Nephrol. 2003 Jun;7(2):144-9. doi: 10.1007/s10157-003-0226-2. Clin Exp Nephrol. 2003. PMID: 14586733

7

Development of hungry bone syndrome after rapid lowering of PTH with intravenous maxacalcitol therapy in a patient with non-uremic secondary hyperparathyroidism.

Kazama JJ, Suzuki K, Yokoseki A, Oyanagi A, Goto S, Shimada H, Maruyama H, Narita I, Gejyo F. Kazama JJ, et al. Clin Nephrol. 2003 Nov;60(5):369-71. doi: 10.5414/cnp60369. Clin Nephrol. 2003. PMID: 14640244

8

[Prevention of dialysis-related amyloidosis].

Yamamoto S, Gejyo F, Kazama JJ. Yamamoto S, et al. Among authors: kazama jj. Nihon Rinsho. 2004 Jun;62 Suppl 6:353-6. Nihon Rinsho. 2004. PMID: 15250323 Review. Japanese. No abstract available.

9

Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.

Oyama Y, Kazama JJ, Omori K, Higuchi N, Kameda S, Yamamoto S, Ito Y, Maruyama H, Narita I, Gejyo F. Oyama Y, et al. Among authors: kazama jj. Clin Exp Nephrol. 2005 Jun;9(2):142-7. doi: 10.1007/s10157-005-0342-2. Clin Exp Nephrol. 2005. PMID: 15980949 Clinical Trial.

10

Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism.

Kazama JJ, Omori K, Takahashi N, Ito Y, Maruyama H, Narita I, Gejyo F, Iwasaki Y, Fukagawa M. Kazama JJ, et al. Clin Nephrol. 2005 Jul;64(1):64-8. doi: 10.5414/cnp64064. Clin Nephrol. 2005. PMID: 16047647

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

243 results

Search Page

Filters